The European Study on Glycogen Storage Disease Type I guidelines originate from 2002 and recommend screening for malignant transformation from HCA to HCC by imaging (ultrasound and MRI‐scan) and by serum alpha‐fetoprotein (AFP) and carcino‐embryonic antigen (CEA).3 The gene discussed is CEACAM5; the disease is hepatocellular carcinoma.